Key Updates
- On Nov. 18, 2026, the Kentucky Board of Pharmacy voted to enforce its existing compounding regulation, 201 KAR 2:076, and decline to grant waivers for compounding six peptide bulk drug substances covered by the new federal enforcement discretion policy.
- The Board confirmed that the federal policy does not authorize compounding with BPC-157, TB-500, Epitalon, Semax, KPV or MOTS-c in or into Kentucky, including by nonresident pharmacies, and that no transition or grace period applies.
Why It Matters
- The Kentucky Board of Pharmacy’s position has immediate implications for resident and nonresident pharmacies serving Kentucky patients, as violations of the state’s compounding requirements may result in disciplinary action against pharmacies and individual licensees.
Next Steps
- Pharmacies serving Kentucky patients should refrain from compounding, dispensing or shipping any of the six identified peptides, review affected inventory and notify prescribers and patients. Pharmacies operating in multiple states should also evaluate applicable state requirements before relying on the federal policy.
Kentucky Declines to Extend Federal Enforcement Discretion
As discussed in our Nov. 9, 2026, client alert, HHS Draws New Lines for Peptide Compounding: What Changes for 503A Pharmacies, the U.S. Department of Health and Human Services (HHS) recently announced an interim enforcement discretion policy under which it generally does not intend to pursue federal enforcement action against Section 503A compounders using six specified peptide bulk drug substances, provided certain conditions are satisfied.
As anticipated in our prior alert, state boards of pharmacy may take a different approach.
On Nov. 19, 2026, the Kentucky Board of Pharmacy (Board) issued a compliance alert confirming that it will not extend similar enforcement discretion under Kentucky law…